<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">F1000Res</journal-id>
<journal-id journal-id-type="iso-abbrev">F1000Res</journal-id>
<journal-id journal-id-type="pmc">F1000Research</journal-id>
<journal-title-group>
<journal-title>F1000Research</journal-title>
</journal-title-group>
<issn pub-type="epub">2046-1402</issn>
<publisher>
<publisher-name>F1000 Research Limited</publisher-name>
<publisher-loc>London, UK</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29636907</article-id>
<article-id pub-id-type="pmc">5871944</article-id>
<article-id pub-id-type="doi">10.12688/f1000research.14056.1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Rett syndrome from bench to bedside: recent advances</article-title>
<fn-group content-type="pub-status">
<fn>
<p>[version 1; referees: 2 approved]</p>
</fn>
</fn-group>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ehinger</surname>
<given-names>Yann</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Writing – Original Draft Preparation</role>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Matagne</surname>
<given-names>Valerie</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Writing – Original Draft Preparation</role>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Villard</surname>
<given-names>Laurent</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Writing – Original Draft Preparation</role>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roux</surname>
<given-names>Jean-Christophe</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Writing – Review &amp; Editing</role>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9721-8844</contrib-id>
<xref ref-type="corresp" rid="c1">a</xref>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<aff id="a1">
<label>1</label>Aix Marseille Univ, INSERM, MMG, 13385 Marseille, France</aff>
</contrib-group>
<author-notes>
<corresp id="c1">
<label>a</label>
<email xlink:href="mailto:Jean-christophe.ROUX@univ-amu.fr">Jean-christophe.ROUX@univ-amu.fr</email>
</corresp>
<fn fn-type="con">
<p>YE, VM, and LV participated in conceptualizing, preparing, and writing the original draft. J-CR participated in conceptualizing, writing, reviewing, and editing the manuscript.</p>
</fn>
<fn fn-type="COI-statement">
<p>No competing interests were disclosed.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>26</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>7</volume>
<elocation-id>398</elocation-id>
<history>
<date date-type="accepted">
<day>21</day>
<month>3</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © 2018 Ehinger Y et al.</copyright-statement>
<copyright-year>2018</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="f1000research-7-15289.pdf" xlink:type="simple"></self-uri>
<abstract>
<p>Rett Syndrome is a severe neurological disorder mainly due to
<italic>de novo</italic> mutations in the methyl-CpG-binding protein 2 gene (
<italic>MECP2</italic>). Mecp2 is known to play a role in chromatin organization and transcriptional regulation. In this review, we report the latest advances on the molecular function of Mecp2 and the new animal and cellular models developed to better study Rett syndrome. Finally, we present the latest innovative therapeutic approaches, ranging from classical pharmacology to correct symptoms to more innovative approaches intended to cure the pathology.</p>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>Rett syndrome</kwd>
<kwd>Mecp2</kwd>
<kwd>treatment</kwd>
</kwd-group>
<funding-group>
<award-group id="fund-1">
<funding-source>INSERM, Aix Marseille University and AFM-Téléthon (Strategic pole MNH Decrypt) and Association Française du Syndrome de Rett (AFSR).</funding-source>
</award-group>
<funding-statement>The authors are supported by INSERM, Aix Marseille University, and grants from the AFM-Téléthon (Strategic pole MNH Decrypt) and Association Française du Syndrome de Rett (AFSR). </funding-statement>
<funding-statement>
<italic>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</italic>
</funding-statement>
</funding-group>
</article-meta>
<notes>
<sec sec-type="editor-note">
<title>Editorial Note on the Review Process</title>
<p>
<ext-link ext-link-type="uri" xlink:href="http://f1000research.com/browse/f1000-faculty-reviews">F1000 Faculty Reviews</ext-link> are commissioned from members of the prestigious
<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/thefaculty">F1000 Faculty</ext-link> and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).</p>
<p>The referees who approved this article are: </p>
<list list-content="reviewer-list" list-type="simple">
<list-item>
<p>
<named-content content-type="reviewer-name">James Eubanks</named-content>, Division of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada
<fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn>
</p>
</list-item>
<list-item>
<p>
<named-content content-type="reviewer-name">Maurizio Desposito</named-content>, Institute of Genetics and Biophysics , Naples, Italy; IRCCS Neuromed, Pozzuoli, Italy
<fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn>
</p>
</list-item>
</list>
</sec>
</notes>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Rett syndrome (RTT) is a severe neurological disorder with an incidence of 1 in about 15,000, which accounts for up to 10% of severe intellectual disability of genetic origin in women
<sup><xref ref-type="bibr" rid="ref-1">1</xref></sup>. The clinical course of the disease consists of an initial normal development until 6 to 18 months of age followed by an arrest of brain development, severely impaired expressive language, the development of stereotypic hand movements, and the appearance of gait ataxia and truncal apraxia/ataxia between 1 and 4 years of age. Other frequent symptoms include breathing dysfunction, electroencephalography (EEG) abnormalities, seizures, spasticity, scoliosis, and reduced growth
<sup><xref ref-type="bibr" rid="ref-2">2</xref>,
<xref ref-type="bibr" rid="ref-3">3</xref></sup>. RTT is caused mainly by
<italic>de novo</italic> mutations in the methyl-CpG-binding protein 2 (
<italic>MECP2</italic>) gene
<sup><xref ref-type="bibr" rid="ref-4">4</xref></sup>.</p>
</sec>
<sec>
<title>MECP2-pathies</title>
<p>In addition to RTT,
<italic>MECP2</italic> mutations have been identified in individuals with syndromes such as mild learning disability in females, neonatal encephalopathy in males, and psychiatric disorders, autism spectrum disorders, and X-linked intellectual disability in both males and females
<sup><xref ref-type="bibr" rid="ref-5">5</xref></sup>. Interestingly, duplication or triplication of the Xq28 region containing the
<italic>MECP2</italic> gene results in a postnatal phenotype, known as the
<italic>MECP2</italic> duplication syndrome, in boys
<sup><xref ref-type="bibr" rid="ref-6">6</xref></sup>. In most cases, the
<italic>MECP2</italic> duplication is inherited from the mother, who expresses a mild to asymptomatic phenotype due to highly skewed X chromosome inactivation (XCI). The main characteristics of this syndrome include early infantile hypotonia, delayed psychomotor development resulting in severe intellectual disability, absent or very limited speech, abnormal gait, epilepsy, and spasticity
<sup><xref ref-type="bibr" rid="ref-7">7</xref></sup>. The finding that MECP2 underexpression or overexpression leads to RTT-like phenotypes raises more than one question: is the severity of MECP2-pathies dependent on
<italic>MECP2</italic> gene dosage? Are therapeutic projects directed at increasing MECP2 levels in patients considered carefully?</p>
</sec>
<sec>
<title>Cell-specific expression of Mecp2</title>
<p>Mecp2 is widely expressed throughout the body and the highest abundance is in postmitotic neurons, where it contributes to the development and maintenance of synapses
<sup><xref ref-type="bibr" rid="ref-8">8</xref></sup>. Moreover, neuron-specific Mecp2 deficiency is sufficient to cause neuronal dysfunction with symptomatic manifestations mimicking the RTT phenotype
<sup><xref ref-type="bibr" rid="ref-9">9</xref></sup>. Since these first findings, the idea that Mecp2 expression was only neuronal has evolved, as Mecp2 was reported in non-neuronal central nervous system (CNS) cells, including astrocytes, microglia, and oligodendrocytes, and cell-specific
<italic>Mecp2</italic> deletion in these cell subtypes appears to contribute to RTT neuropathology
<sup><xref ref-type="bibr" rid="ref-10">10</xref>,
<xref ref-type="bibr" rid="ref-11">11</xref></sup>.</p>
<p>Astrocytes were the first non-neuronal cells reported to express Mecp2 and to play a key role in neuronal morphology
<sup><xref ref-type="bibr" rid="ref-10">10</xref>,
<xref ref-type="bibr" rid="ref-12">12</xref></sup> and RTT symptom progression
<sup><xref ref-type="bibr" rid="ref-13">13</xref></sup>. Astrocytes lacking Mecp2 exhibit abnormal features. For instance, microtubule-dependent vesicle transport is altered in Mecp2-deficient astrocytes from Mecp2-deficient mice
<sup><xref ref-type="bibr" rid="ref-14">14</xref></sup>. In addition, recent evidence suggests a role of mutant astrocytes in breathing deficits due to a lower chemosensitivity
<sup><xref ref-type="bibr" rid="ref-15">15</xref>,
<xref ref-type="bibr" rid="ref-16">16</xref></sup>. Mutant astrocytes were also very recently involved in an abnormal regulation of excitatory synaptic signaling in Mecp2-deficient mice
<sup><xref ref-type="bibr" rid="ref-17">17</xref></sup>.</p>
<p>A role for microglia in RTT neuropathology was also reported by Derecki
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-18">18</xref></sup>. Their findings were very interesting, as they showed that grafting wild-type myeloid cells in irradiated
<italic>Mecp2</italic>-null mice led to repopulation of the brain parenchyma by microglia-like myeloid cells and a reduction in the vast majority of disease-associated abnormalities
<sup><xref ref-type="bibr" rid="ref-18">18</xref></sup>. Unfortunately, subsequent studies failed to reproduce these findings
<sup><xref ref-type="bibr" rid="ref-19">19</xref></sup>, and, although Mecp2 deregulation in microglia was shown to affect other immune functions
<sup><xref ref-type="bibr" rid="ref-20">20</xref>,
<xref ref-type="bibr" rid="ref-21">21</xref></sup>, the mechanisms explaining how microglia might contribute to these modifications remain mostly unknown. One possible explanation is that microglia contributes to end stages of the disease by dismantling neural circuits rendered vulnerable by the lack of Mecp2
<sup><xref ref-type="bibr" rid="ref-22">22</xref></sup>.</p>
<p>Oligodendrocytes were also involved in RTT neuropathology, as the expression of Mecp2 specifically in oligodendrocytes alleviated some of the RTT phenotype
<sup><xref ref-type="bibr" rid="ref-23">23</xref></sup>. The level of some myelin-related proteins was also deregulated in the brain of
<italic>Mecp2</italic>-null mice
<sup><xref ref-type="bibr" rid="ref-23">23</xref></sup>, and Mecp2 was reported to regulate the expression of myelin genes in rat oligodendrocytes
<sup><xref ref-type="bibr" rid="ref-24">24</xref></sup>. Altogether, Mecp2 is currently known to play a role in most cell types of the CNS.</p>
</sec>
<sec>
<title>Mecp2 binding and transcriptional regulation</title>
<p>Mecp2 is a member of the methyl-CpG-binding domain (MBD) family of proteins
<sup><xref ref-type="bibr" rid="ref-25">25</xref>–
<xref ref-type="bibr" rid="ref-27">27</xref></sup> that are known to play a role in chromatin organization and transcriptional regulation through binding to methylated CpG sites or 5-hydroxymethylcytosine
<sup><xref ref-type="bibr" rid="ref-28">28</xref>,
<xref ref-type="bibr" rid="ref-29">29</xref></sup>. Since then, Guo
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-30">30</xref></sup> have shown that Mecp2 was also able to bind to methylated CpA
<sup><xref ref-type="bibr" rid="ref-30">30</xref></sup>, and Sugino
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-31">31</xref></sup> showed that Mecp2 repression was biased toward long genes. In 2015, the Greenberg lab revealed that that bias was achieved through binding to mCAs that were more frequent within these long genes
<sup><xref ref-type="bibr" rid="ref-32">32</xref></sup>. Recently, the third base following mCA was shown to strongly affect Mecp2 binding, and the strongest binding was the tri-nucleotide sequence mCAC
<sup><xref ref-type="bibr" rid="ref-33">33</xref></sup>. Further studies will be necessary to determine whether Mecp2 binding to either mCG or mCAC leads to different biological responses.</p>
<p>Mecp2 was found to be expressed in mouse embryonic development from E10.5
<sup><xref ref-type="bibr" rid="ref-8">8</xref></sup>. Stroud
<italic>et al</italic>. recently showed that a DNA methyltransferase (DNMT3A) binds to lowly expressed genes in embryonic stages leading to CA methylation, which subsequently recruits Mecp2 and enables gene repression in the maturing brain
<sup><xref ref-type="bibr" rid="ref-34">34</xref></sup>.</p>
<p>In addition to directly binding to methylated DNA, Mecp2 was found to regulate gene transcription through the recruitment of corepressors such as the NCoR/SMRT corepressor complex
<sup><xref ref-type="bibr" rid="ref-35">35</xref></sup>. Using a highly truncated version of Mecp2 retaining the MBD domain, the NLS, and the NCoR/SMRT signals, the team of Adrian Bird demonstrated that almost all functions of the Mecp2 protein were maintained, definitively demonstrating the leading role of this complex in the pathology
<sup><xref ref-type="bibr" rid="ref-36">36</xref></sup>.</p>
<p>Finally, Mecp2 directly modulates chromatin architecture via its three AT-hook-like domains
<sup><xref ref-type="bibr" rid="ref-37">37</xref></sup>. AT-hooks are short DNA-binding motifs that interact with the wide minor groove of AT-rich DNA regions. A study proposed that AT-hooks function as secondary DNA-binding domains either stabilizing or modulating the association of Mecp2 to chromatin. The authors also state that this secondary role is supported by the absence of RTT-causing missense mutations at these AT-hooks sites
<sup><xref ref-type="bibr" rid="ref-38">38</xref></sup>. This view may be challenged by recent findings showing that a mouse carrying an eight-amino-acid deletion in the AT-hook domain 1 exhibited locomotor and cognitive dysfunctions
<sup><xref ref-type="bibr" rid="ref-39">39</xref></sup>.</p>
<p>These recent findings highlight the complexity of mechanisms by which Mecp2 plays its role of transcriptional regulator and partly explains why therapies other than those aimed at correcting/replacing Mecp2 are able to improve only some of the symptoms in patients with RTT (see below).</p>
</sec>
<sec>
<title>Preclinical models of Rett syndrome</title>
<p>Several RTT mouse models have been developed and provided scientists with invaluable tools to understand the neurobiological mechanisms underlying RTT. Over the past three years, thanks to new gene-editing methods such as the transcription activator-like effector nucleases (TALENs), zinc finger nuclease technology, and the CRISPR-Cas9 system, models in species other than mice have been developed
<sup><xref ref-type="bibr" rid="ref-40">40</xref></sup>.</p>
<p>In 2016, two novel
<italic>Mecp2</italic>-knockout rat models have been developed by using zinc finger nuclease technology. In the first one, rats present a deletion of exon 4, leading to the complete absence of the Mecp2 protein
<sup><xref ref-type="bibr" rid="ref-41">41</xref></sup>.
<italic>Mecp2</italic>-null rats recapitulate general RTT features such as growth retardation, malocclusion, hypoactivity, and early death. Null rats exhibit weaker forelimb grip strength and reduced locomotion activity. Breathing abnormalities such as hyperventilation and high apnea rate were found, and this is similar to what is seen in RTT patients and mice. In the second model
<sup><xref ref-type="bibr" rid="ref-42">42</xref></sup>, a
<italic>Mecp2</italic>-knockout rat was generated and here too the rats presented a symptom progression close to that of the RTT mice. Male rats showed an advanced disease time course and a shorter lifespan compared with female rats. Female Mecp2-deficient rats also recapitulated the motor and behavioral phenotype observed in existing mouse models. More recently, two studies published by the Smith lab showed neuronal cytoskeletal gene dysregulation and mechanical hypersensitivity in the male rat model and non-cognitive deficits (motor, somatosensory, viscerosensory, and metabolic impairments) in the female rat model
<sup><xref ref-type="bibr" rid="ref-43">43</xref>,
<xref ref-type="bibr" rid="ref-44">44</xref></sup>. To date, research using these new rat models has confirmed the observations made in the mouse; it will be interesting to see whether future studies will only replicate and validate results obtained in the mouse or bring new findings specific to the rat.</p>
<p>In 2014, the first non-human primate carrying a
<italic>MECP2</italic> mutation using TALEN-mediated gene targeting was generated
<sup><xref ref-type="bibr" rid="ref-45">45</xref></sup>. The authors obtained one male cynomolgus monkey with a
<italic>MECP2</italic> deletion out of the 51 TALEN-injected embryos. They suggest that the low pregnancy and survival rates could be due to TALEN toxicity or that the TALEN-mediated deletion in males could be lethal, such as in the human disease. A mosaicism of
<italic>MECP2</italic> deletion was found in the monkey and could be due to a delayed TALEN targeting during embryonic development. The monkey failed to survive, but these results demonstrated the feasibility of
<italic>MECP2</italic> editing in non-human primates. In 2017, the same group published a study reporting five living
<italic>MECP2</italic>-mutant females
<sup><xref ref-type="bibr" rid="ref-46">46</xref></sup>. Magnetic resonance imaging scanning showed significantly reduced cortical gray matter volumes in mutant monkey brains. In addition, mutant monkeys displayed behavioral features such as fragmented sleep, increased stereotypy, and reduced environmental exploration, but no differences in body weight and head circumference were observed. This study seems to validate a robust female monkey model displaying RTT features—such as male embryonic lethality, social withdrawal, and eye-tracking defect—absent in rodent models. This model will be invaluable to investigate therapies, such as gene therapy, that need to be transferred to the clinics and may be impacted by the species barrier. However, given the slower development in the monkey, their longer lifespan, and the cost involved in caring for and maintaining their well-being, it is quite obvious that smaller animal models (rodents and zebra fish) will be the first ones to be used in RTT mechanisms and therapy screening studies.</p>
</sec>
<sec>
<title>
<italic>In vitro</italic> models of Rett syndrome</title>
<p>Besides animal models, the use of neuronal cultures has facilitated the understanding of Mecp2’s molecular functions. However, until recently, only rodent primary neurons and human immortalized cell lines were available. Thanks to the forced reprogramming of human somatic cells into induced pluripotent stem cells (iPSCs)
<sup><xref ref-type="bibr" rid="ref-47">47</xref></sup>, human neurons (or any other cell type) can be generated from cells of patients with RTT and be used to study RTT. Using human iPSCs, a recent study showed that the lack of MECP2 led to the de-repression of genes on the inactive X chromosome and to transcriptional deregulations of mitochondrial membrane proteins
<sup><xref ref-type="bibr" rid="ref-48">48</xref></sup>. The use of astrocytes differentiated from RTT human iPSCs showed a profound transcriptional deregulation in MECP2-deficient cells
<sup><xref ref-type="bibr" rid="ref-49">49</xref></sup> and confirmed that astrocyte-conditioned medium had adverse effects on the cellular physiology and morphology of wild-type neurons
<sup><xref ref-type="bibr" rid="ref-12">12</xref></sup>. Using neurons differentiated from MECP2-deficient iPSCs, another study showed a significant deficit in KCC2 expression, a key factor for chloride neuronal homeostasis. These cells consequently have a delayed GABA functional switch from excitation to inhibition. Interestingly, overexpression of KCC2 in these MECP2-deficient neurons rescued GABA functional deficits, suggesting an important role of KCC2 in RTT neuropathology
<sup><xref ref-type="bibr" rid="ref-50">50</xref></sup>. In addition to confirming previously described abnormalities in patients with RTT or in mouse models, iPSC deficits can partially be rescued by insulin-like growth factor 1 (IGF-1) treatment
<sup><xref ref-type="bibr" rid="ref-12">12</xref></sup>, as was previously shown in an RTT mouse model
<sup><xref ref-type="bibr" rid="ref-51">51</xref></sup>. Overall, iPSCs seem to display cellular phenotypes similar to those seen in RTT mouse models and should prove useful in high-throughput screening of new therapeutic compounds.</p>
</sec>
<sec>
<title>Therapeutic approaches</title>
<sec>
<title>Gene therapy</title>
<p>As previously mentioned, RTT was shown to be fully reversible in a mouse model of the disease
<sup><xref ref-type="bibr" rid="ref-52">52</xref></sup>, indicating that it could be amenable to gene therapy. This is of primary importance, as most RTT mutations occur
<italic>de novo</italic> and the disease is usually diagnosed when the symptoms are present, which also means that any therapeutic intervention will be administered to RTT patients after disease onset. Moreover, in order to be efficient, any gene therapy vector will have to reach the whole CNS, as it is globally affected in RTT. Gadalla
<italic>et al</italic>. showed, as a proof of principle, a considerable improvement when neonatal RTT male mice were administered a gene therapy vector expressing the human MECP2e1 isoform by intracranial delivery
<sup><xref ref-type="bibr" rid="ref-53">53</xref></sup>. The phenotypic rescue was less pronounced when a more translational approach (that is, systemic administration of the therapeutic vector in juvenile RTT mice) was used. This first publication was followed by a second one reporting similar results in male RTT mice as well as a phenotypic improvement in female RTT mice
<sup><xref ref-type="bibr" rid="ref-54">54</xref></sup>. More recently, our lab has shown that using a codon-optimized Mecp2e1 isoform improved RTT symptoms, including breathing defects, which had not been shown before
<sup><xref ref-type="bibr" rid="ref-55">55</xref></sup>. Although these results seemed very promising, some severe side effects have been reported after the administration of high doses of therapeutic vector, which has led to the development of second-generation therapeutic vectors devoid of side effects but with decreased therapeutic efficacy
<sup><xref ref-type="bibr" rid="ref-56">56</xref></sup>. Another study, focusing on the route of administration, showed that this second-generation vector had better efficacy when administered via an intra-cerebrospinal fluid route
<sup><xref ref-type="bibr" rid="ref-57">57</xref></sup>. Recently, the neonatal intracranial administration of a truncated Mecp2 was also shown to partially rescue the RTT phenotype
<sup><xref ref-type="bibr" rid="ref-36">36</xref></sup>, which shows that gene therapy can still be improved and benefit from new discoveries related to Mecp2 biology. Expressing Mecp2 in cases of loss-of-function mutation seems the best option, but what about cases in which a missense mutation leads to the expression of a non-functional Mecp2 protein? Will it act in a dominant-negative manner and prevent a healthy Mecp2 from manifesting its rescuing effect? A study by Gadalla
<italic>et al</italic>. indicates that gene therapy would also work in the case of certain missense mutations, since the therapeutic vector was able to improve the RTT symptoms in a knock-in RTT mouse model (T158M)
<sup><xref ref-type="bibr" rid="ref-56">56</xref></sup>. Another therapeutic approach would be to directly correct the missense mutation by gene editing, as was done for a
<italic>MECP2</italic> duplication with the CRISPR-Cas9 system
<sup><xref ref-type="bibr" rid="ref-58">58</xref></sup>, or by RNA editing using the natural editing capability of the adenosine deaminases acting on RNA (ADAR) to correct G&gt;A mutations
<sup><xref ref-type="bibr" rid="ref-59">59</xref></sup>. However, these techniques are still in their infancy and so far their efficacy has been shown only
<italic>in vitro</italic>.</p>
</sec>
<sec>
<title>X chromosome reactivation</title>
<p>In female cells, one X chromosome is randomly inactivated and this ensures the same expression of X-linked genes in both male and female cells. Therefore, in female patients with RTT, about half the cells express the mutant version of MECP2 while the other half expresses a normal MECP2 protein. Reactivation of the inactivated X chromosome (Xi), or at least of the (normal) inactivated MECP2 allele, could potentially cure RTT. In order to identify molecules involved in Xi reactivation, a short hairpin RNA (shRNA) library was used in two different studies
<sup><xref ref-type="bibr" rid="ref-60">60</xref>,
<xref ref-type="bibr" rid="ref-61">61</xref></sup> and led to the discovery of factors modulating XCI, including PDPK1 (3-phosphoinositide-dependent protein kinase 1) and AKA (Aurora kinase A), whose
<italic>in vitro</italic> pharmacological inhibition was able to reactivate the Xi
<sup><xref ref-type="bibr" rid="ref-60">60</xref></sup>. In addition to those factors common to the two studies, Sripathy
<italic>et al</italic>. reported that the BMP/TGFb pathway was strongly involved in XCI both
<italic>in vitro</italic> and
<italic>in vivo</italic>
<sup><xref ref-type="bibr" rid="ref-61">61</xref></sup>. In another study, by combining a gene knockdown strategy using antisense oligonucleotides against Xist, one of the key XCI regulators, and a pharmacological approach, Carrette
<italic>et al</italic>. demonstrated a synergistic effect on Xi reactivation
<italic>in vitro</italic> and
<italic>in vivo</italic>
<sup><xref ref-type="bibr" rid="ref-62">62</xref></sup>. These studies indicate that Xi reactivation is possible; however, the challenge now will be to translate these results into safe therapeutic interventions. The main issue will be to determine the impact of the induced global X-linked protein overdose following Xi reactivation.</p>
</sec>
</sec>
<sec>
<title>Clinical trials</title>
<p>Since 1966 and the first clinical description of RTT, over 25 clinical trials testing therapeutic agents targeting motor, cognitive, and autonomous dysfunctions have been initiated. For instance, breathing abnormalities such as apneas, which are crucial in RTT, have been targeted by several molecules, including desipramine
<sup><xref ref-type="bibr" rid="ref-37">37</xref></sup>, sarizotan
<sup><xref ref-type="bibr" rid="ref-63">63</xref></sup> (ClinicalTrials.gov identifier NCT02790034), and ketamine
<sup><xref ref-type="bibr" rid="ref-63">63</xref>,
<xref ref-type="bibr" rid="ref-64">64</xref></sup> (ClinicalTrials.gov identifier NCT02562820). Desipramine, an inhibitor of noradrenaline reuptake, was successfully tested in a preclinical study, reducing apneas and rescuing breathing anomalies in a mouse model of RTT, probably by increasing the number of tyrosine hydroxylase (TH) neurons in the brainstem
<sup><xref ref-type="bibr" rid="ref-65">65</xref></sup>. The recent desipramine clinical trial did not reveal a clinical improvement in all patients with RTT, but the authors did find an inverse correlation between desipramine concentration and the number of apneas
<sup><xref ref-type="bibr" rid="ref-37">37</xref></sup>. Mirtazapine, a desipramine acting-like molecule without its side effects, showed promising preclinical results in RTT mice and could be the next drug of interest
<sup><xref ref-type="bibr" rid="ref-66">66</xref></sup>. On the basis of translational studies
<sup><xref ref-type="bibr" rid="ref-64">64</xref>,
<xref ref-type="bibr" rid="ref-67">67</xref></sup>, patients are currently being recruited for the sarizotan clinical trial and the one evaluating the efficacy of ketamine is under way.</p>
<p>Brain-derived neurotrophic factor (BDNF) is an important neurotrophic factor playing a key role in RTT; indeed, its deregulation seems strongly correlated with the reduction of dendritic arborization identified in RTT and its overexpression in
<italic>Mecp2</italic>-knockout mice partially rescues their phenotype
<sup><xref ref-type="bibr" rid="ref-68">68</xref>,
<xref ref-type="bibr" rid="ref-69">69</xref></sup>. These different points make the BDNF pathway one of the most appealing pathways to target in RTT
<sup><xref ref-type="bibr" rid="ref-70">70</xref></sup>. BDNF itself is unable to cross the blood-brain barrier (BBB) and needs to be indirectly activated. Fingolimod is able to increase BDNF expression and improved locomotor activity, sensorimotor coordination, and lifespan in RTT mice
<sup><xref ref-type="bibr" rid="ref-71">71</xref></sup>, and a clinical trial (ClinicalTrials.gov identifier NCT02061137) is under way. Glatiramer acetate, another BDNF secretion inducer, was first tested on a small cohort of patients with RTT, and an improvement of gait velocity was reported
<sup><xref ref-type="bibr" rid="ref-72">72</xref></sup>. A second clinical trial had to be stopped because of a severe adverse effect on patients
<sup><xref ref-type="bibr" rid="ref-73">73</xref></sup>. Unlike BDNF, IGF-1 crosses the BBB and activates similar intracellular pathways. Two preclinical studies in RTT mice reported the positive effect of IGF-1
<sup><xref ref-type="bibr" rid="ref-50">50</xref>,
<xref ref-type="bibr" rid="ref-74">74</xref></sup>. The IGF-1 full-length, also named mecasermin, was tested in three clinical studies
<sup><xref ref-type="bibr" rid="ref-75">75</xref>–
<xref ref-type="bibr" rid="ref-77">77</xref></sup>. A total of 10 patients with RTT treated in a preliminary 20-week open-label assessment with mecasermin showed a reduction in the incidence of apneas and improvements of deleterious neurological consequences, including depression and anxiety
<sup><xref ref-type="bibr" rid="ref-75">75</xref></sup>. However, a recent placebo-controlled crossover clinical trial on 30 patients with RTT did not succeed in confirming the improvements observed in the previous study
<sup><xref ref-type="bibr" rid="ref-77">77</xref></sup>. After a pilot study investigating the safety of the IGF-1 tripeptide form
<sup><xref ref-type="bibr" rid="ref-78">78</xref></sup>, a clinical trial with trofinetide (an analogue of the IGF-1 tripeptide) was recently published and presented improvements in core features of RTT
<sup><xref ref-type="bibr" rid="ref-79">79</xref></sup>.</p>
<p>A disruption in the balance between excitation and inhibition and between GABA and glutamate pathways is implicated in RTT
<sup><xref ref-type="bibr" rid="ref-80">80</xref></sup>. Dextromethorphan, an NMDA receptor antagonist, has been tested for its capacity to restore normal EEG function and reduce seizure, and although no significant improvement in global severity was noticed, statistically significant changes were seen in clinical seizures, language, and behavioral hyperactivity
<sup><xref ref-type="bibr" rid="ref-81">81</xref></sup>.</p>
<p>Recent studies have suggested a systemic redox imbalance in a mouse model and in patients with RTT
<sup><xref ref-type="bibr" rid="ref-82">82</xref>–
<xref ref-type="bibr" rid="ref-84">84</xref></sup>. Polyunsaturated fatty acids (PUFAs) are US Food and Drug Administration-approved oils that act indirectly on this cellular redox imbalance. In two clinical trials, PUFA dietary supplementation was able to reduce oxidative stress markers and improve the biventricular myocardial systolic function
<sup><xref ref-type="bibr" rid="ref-85">85</xref>,
<xref ref-type="bibr" rid="ref-86">86</xref></sup>.</p>
<p>The abovementioned clinical trials all originated from preclinical studies that identified promising therapeutic molecules. In most cases, and as seen in preclinical studies, these treatments improved some RTT symptoms. However, one cannot help noticing that these therapeutic benefits are restricted to a (sometimes small) subset of symptoms. These last few years have been marked by a large improvement in innovative therapeutic strategies, such as gene therapy and gene editing. These new approaches are being applied to the RTT field and have already been the subject of a few publications. Unlike pharmacological approaches, these techniques are aimed at curing the disease rather than alleviating RTT symptoms, raising great hope for patients with RTT and their families. However, these first publications also highlighted the need for increased safety, given the irrevocable nature of the proposed treatments.</p>
</sec>
<sec sec-type="conclusions">
<title>Conclusions</title>
<p>Since the gene responsible for RTT was identified almost 20 years ago
<sup><xref ref-type="bibr" rid="ref-4">4</xref></sup>, a stupefying number of research projects aimed at understanding the mechanisms underlying this pathology and identifying potential therapeutic targets have been conducted. From these studies have stemmed many of the clinical trials whose results have recently been published. Even though many trials reported improvements, these were disappointingly small and restricted to a few symptoms at a time. This may be explained in part by the complex and often controversial functions of Mecp2 that have been unveiled throughout the years: from simple transcriptional repressor to genome-wide noise dampener and from a simple CpG MBD to a protein-binding multiple nucleotide sequence. The study of Mecp2 biology revealed an unexpected complexity, and this probably explains why Mecp2 replacement therapies such as gene therapy, gene editing, or X chromosome reactivation are now thought to be the best options to dramatically improve RTT or one day cure it.</p>
</sec>
</body>
<back>
<ref-list>
<ref id="ref-1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>DD</given-names></name></person-group>:
<article-title>Review of Rett syndrome.</article-title>
<source/><italic>J Neuropathol Exp Neurol.</italic>
<year>1997</year>;<volume>56</volume>(<issue>8</issue>):<fpage>843</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="pmid">9258253</pub-id></mixed-citation>
</ref>
<ref id="ref-2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Neul</surname><given-names>JL</given-names></name><name><surname>Kaufmann</surname><given-names>WE</given-names></name><name><surname>Glaze</surname><given-names>DG</given-names></name><etal></etal></person-group>:
<article-title>Rett syndrome: revised diagnostic criteria and nomenclature.</article-title>
<source/><italic>Ann Neurol.</italic>
<year>2010</year>;<volume>68</volume>(<issue>6</issue>):<fpage>944</fpage>–<lpage>50</lpage>.
<pub-id pub-id-type="doi">10.1002/ana.22124</pub-id>
<!--<pub-id pub-id-type="pmcid">3058521</pub-id>-->
<pub-id pub-id-type="pmid">21154482</pub-id></mixed-citation>
</ref>
<ref id="ref-3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hagberg</surname><given-names>B</given-names></name><name><surname>Goutières</surname><given-names>F</given-names></name><name><surname>Hanefeld</surname><given-names>F</given-names></name><etal></etal></person-group>:
<article-title>Rett syndrome: criteria for inclusion and exclusion.</article-title>
<source/><italic>Brain Dev.</italic>
<year>1985</year>;<volume>7</volume>(<issue>3</issue>):<fpage>372</fpage>–<lpage>3</lpage>.
<pub-id pub-id-type="doi">10.1016/S0387-7604(85)80048-6</pub-id>
<pub-id pub-id-type="pmid">4061772</pub-id></mixed-citation>
</ref>
<ref id="ref-4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amir</surname><given-names>RE</given-names></name><name><surname>Van den Veyver</surname><given-names>IB</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2.</article-title>
<source/><italic>Nat Genet.</italic>
<year>1999</year>;<volume>23</volume>(<issue>2</issue>):<fpage>185</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1038/13810</pub-id>
<pub-id pub-id-type="pmid">10508514</pub-id></mixed-citation>
</ref>
<ref id="ref-5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lombardi</surname><given-names>LM</given-names></name><name><surname>Baker</surname><given-names>SA</given-names></name><name><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group>:
<article-title>
<italic>MECP2</italic> disorders: from the clinic to mice and back.</article-title>
<source/><italic>J Clin Invest.</italic>
<year>2015</year>;<volume>125</volume>(<issue>8</issue>):<fpage>2914</fpage>–<lpage>23</lpage>.
<pub-id pub-id-type="doi">10.1172/JCI78167</pub-id>
<!--<pub-id pub-id-type="pmcid">4563741</pub-id>-->
<pub-id pub-id-type="pmid">26237041</pub-id></mixed-citation>
</ref>
<ref id="ref-6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Collins</surname><given-names>AL</given-names></name><name><surname>Levenson</surname><given-names>JM</given-names></name><name><surname>Vilaythong</surname><given-names>AP</given-names></name><etal></etal></person-group>:
<article-title>Mild overexpression of MeCP2 causes a progressive neurological disorder in mice.</article-title>
<source/><italic>Hum Mol Genet.</italic>
<year>2004</year>;<volume>13</volume>(<issue>21</issue>):<fpage>2679</fpage>–<lpage>89</lpage>.
<pub-id pub-id-type="doi">10.1093/hmg/ddh282</pub-id>
<pub-id pub-id-type="pmid">15351775</pub-id></mixed-citation>
</ref>
<ref id="ref-7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Esch</surname><given-names>H</given-names></name></person-group>:
<article-title>
<italic>MECP2</italic> Duplication Syndrome.</article-title>
<source/><italic>Mol Syndromol.</italic>
<year>2012</year>;<volume>2</volume>(<issue>3–5</issue>):<fpage>128</fpage>–<lpage>36</lpage>.
<pub-id pub-id-type="doi">10.1159/000329580</pub-id>
<!--<pub-id pub-id-type="pmcid">3366699</pub-id>-->
<pub-id pub-id-type="pmid">22679399</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/717347802">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shahbazian</surname><given-names>MD</given-names></name><name><surname>Antalffy</surname><given-names>B</given-names></name><name><surname>Armstrong</surname><given-names>DL</given-names></name><etal></etal></person-group>:
<article-title>Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation.</article-title>
<source/><italic>Hum Mol Genet.</italic>
<year>2002</year>;<volume>11</volume>(<issue>2</issue>):<fpage>115</fpage>–<lpage>24</lpage>.
<pub-id pub-id-type="doi">10.1093/hmg/11.2.115</pub-id>
<pub-id pub-id-type="pmid">11809720</pub-id></mixed-citation>
</ref>
<ref id="ref-9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>RZ</given-names></name><name><surname>Akbarian</surname><given-names>S</given-names></name><name><surname>Tudor</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice.</article-title>
<source/><italic>Nat Genet.</italic>
<year>2001</year>;<volume>27</volume>(<issue>3</issue>):<fpage>327</fpage>–<lpage>31</lpage>.
<pub-id pub-id-type="doi">10.1038/85906</pub-id>
<pub-id pub-id-type="pmid">11242118</pub-id></mixed-citation>
</ref>
<ref id="ref-10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ballas</surname><given-names>N</given-names></name><name><surname>Lioy</surname><given-names>DT</given-names></name><name><surname>Grunseich</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology.</article-title>
<source/><italic>Nat Neurosci.</italic>
<year>2009</year>;<volume>12</volume>(<issue>3</issue>):<fpage>311</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1038/nn.2275</pub-id>
<!--<pub-id pub-id-type="pmcid">3134296</pub-id>-->
<pub-id pub-id-type="pmid">19234456</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/1161225">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>MV</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Felice</surname><given-names>CA</given-names></name><etal></etal></person-group>:
<article-title>MeCP2 is critical for maintaining mature neuronal networks and global brain anatomy during late stages of postnatal brain development and in the mature adult brain.</article-title>
<source/><italic>J Neurosci.</italic>
<year>2012</year>;<volume>32</volume>(<issue>29</issue>):<fpage>10021</fpage>–<lpage>34</lpage>.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1316-12.2012</pub-id>
<!--<pub-id pub-id-type="pmcid">3461266</pub-id>-->
<pub-id pub-id-type="pmid">22815516</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/719869421">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams</surname><given-names>EC</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name><name><surname>Mohamed</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons.</article-title>
<source/><italic>Hum Mol Genet.</italic>
<year>2014</year>;<volume>23</volume>(<issue>11</issue>):<fpage>2968</fpage>–<lpage>80</lpage>.
<pub-id pub-id-type="doi">10.1093/hmg/ddu008</pub-id>
<!--<pub-id pub-id-type="pmcid">4014193</pub-id>-->
<pub-id pub-id-type="pmid">24419315</pub-id></mixed-citation>
</ref>
<ref id="ref-13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lioy</surname><given-names>DT</given-names></name><name><surname>Garg</surname><given-names>SK</given-names></name><name><surname>Monaghan</surname><given-names>CE</given-names></name><etal></etal></person-group>:
<article-title>A role for glia in the progression of Rett's syndrome.</article-title>
<source/><italic>Nature.</italic>
<year>2011</year>;<volume>475</volume>(<issue>7357</issue>):<fpage>497</fpage>–<lpage>500</lpage>.
<pub-id pub-id-type="doi">10.1038/nature10214</pub-id>
<!--<pub-id pub-id-type="pmcid">3268776</pub-id>-->
<pub-id pub-id-type="pmid">21716289</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/13276960">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Delépine</surname><given-names>C</given-names></name><name><surname>Meziane</surname><given-names>H</given-names></name><name><surname>Nectoux</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>Altered microtubule dynamics and vesicular transport in mouse and human MeCP2-deficient astrocytes.</article-title>
<source/><italic>Hum Mol Genet.</italic>
<year>2016</year>;<volume>25</volume>(<issue>1</issue>):<fpage>146</fpage>–<lpage>57</lpage>.
<pub-id pub-id-type="doi">10.1093/hmg/ddv464</pub-id>
<!--<pub-id pub-id-type="pmcid">4690499</pub-id>-->
<pub-id pub-id-type="pmid">26604147</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725960660">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garg</surname><given-names>SK</given-names></name><name><surname>Lioy</surname><given-names>DT</given-names></name><name><surname>Knopp</surname><given-names>SJ</given-names></name><etal></etal></person-group>:
<article-title>Conditional depletion of methyl-CpG-binding protein 2 in astrocytes depresses the hypercapnic ventilatory response in mice.</article-title>
<source/><italic>J Appl Physiol (1985).</italic>
<year>2015</year>;<volume>119</volume>(<issue>6</issue>):<fpage>670</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1152/japplphysiol.00411.2015</pub-id>
<pub-id pub-id-type="pmid">26205541</pub-id></mixed-citation>
</ref>
<ref id="ref-16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Turovsky</surname><given-names>E</given-names></name><name><surname>Karagiannis</surname><given-names>A</given-names></name><name><surname>Abdala</surname><given-names>AP</given-names></name><etal></etal></person-group>:
<article-title>Impaired CO
<sub>2</sub> sensitivity of astrocytes in a mouse model of Rett syndrome.</article-title>
<source/><italic>J Physiol.</italic>
<year>2015</year>;<volume>593</volume>(<issue>14</issue>):<fpage>3159</fpage>–<lpage>68</lpage>.
<pub-id pub-id-type="doi">10.1113/JP270369</pub-id>
<!--<pub-id pub-id-type="pmcid">4532534</pub-id>-->
<pub-id pub-id-type="pmid">25981852</pub-id></mixed-citation>
</ref>
<ref id="ref-17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rakela</surname><given-names>B</given-names></name><name><surname>Brehm</surname><given-names>P</given-names></name><name><surname>Mandel</surname><given-names>G</given-names></name></person-group>:
<article-title>Astrocytic modulation of excitatory synaptic signaling in a mouse model of Rett syndrome.</article-title>
<source/><italic>eLife.</italic>
<year>2018</year>;<volume>7</volume>: pii: e31629.
<pub-id pub-id-type="doi">10.7554/eLife.31629</pub-id>
<!--<pub-id pub-id-type="pmcid">5771668</pub-id>-->
<pub-id pub-id-type="pmid">29313799</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/732437997">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Derecki</surname><given-names>NC</given-names></name><name><surname>Cronk</surname><given-names>JC</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><etal></etal></person-group>:
<article-title>Wild-type microglia arrest pathology in a mouse model of Rett syndrome.</article-title>
<source/><italic>Nature.</italic>
<year>2012</year>;<volume>484</volume>(<issue>7392</issue>):<fpage>105</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1038/nature10907</pub-id>
<!--<pub-id pub-id-type="pmcid">3321067</pub-id>-->
<pub-id pub-id-type="pmid">22425995</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/14216958">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wegener</surname><given-names>JE</given-names></name><name><surname>Huang</surname><given-names>TW</given-names></name><etal></etal></person-group>:
<article-title>Wild-type microglia do not reverse pathology in mouse models of Rett syndrome.</article-title>
<source/><italic>Nature.</italic>
<year>2015</year>;<volume>521</volume>(<issue>7552</issue>):<fpage>E1</fpage>–<lpage>4</lpage>.
<pub-id pub-id-type="doi">10.1038/nature14444</pub-id>
<!--<pub-id pub-id-type="pmcid">4684952</pub-id>-->
<pub-id pub-id-type="pmid">25993969</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725522839">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cronk</surname><given-names>JC</given-names></name><name><surname>Derecki</surname><given-names>NC</given-names></name><name><surname>Ji</surname><given-names>E</given-names></name><etal></etal></person-group>:
<article-title>Methyl-CpG Binding Protein 2 Regulates Microglia and Macrophage Gene Expression in Response to Inflammatory Stimuli.</article-title>
<source/><italic>Immunity.</italic>
<year>2015</year>;<volume>42</volume>(<issue>4</issue>):<fpage>679</fpage>–<lpage>91</lpage>.
<pub-id pub-id-type="doi">10.1016/j.immuni.2015.03.013</pub-id>
<!--<pub-id pub-id-type="pmcid">4407145</pub-id>-->
<pub-id pub-id-type="pmid">25902482</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725444711">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cronk</surname><given-names>JC</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>TS</given-names></name><etal></etal></person-group>:
<article-title>Influenza A induces dysfunctional immunity and death in MeCP2-overexpressing mice.</article-title>
<source/><italic>JCI Insight.</italic>
<year>2017</year>;<volume>2</volume>(<issue>2</issue>):<fpage>e88257</fpage>.
<pub-id pub-id-type="doi">10.1172/jci.insight.88257</pub-id>
<!--<pub-id pub-id-type="pmcid">5256138</pub-id>-->
<pub-id pub-id-type="pmid">28138553</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727256637">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schafer</surname><given-names>DP</given-names></name><name><surname>Heller</surname><given-names>CT</given-names></name><name><surname>Gunner</surname><given-names>G</given-names></name><etal></etal></person-group>:
<article-title>Microglia contribute to circuit defects in
<italic>Mecp2 null</italic> mice independent of microglia-specific loss of Mecp2 expression.</article-title>
<source/><italic>eLife.</italic>
<year>2016</year>;<volume>5</volume>: pii: e15224.
<pub-id pub-id-type="doi">10.7554/eLife.15224</pub-id>
<!--<pub-id pub-id-type="pmcid">4961457</pub-id>-->
<pub-id pub-id-type="pmid">27458802</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726577718">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>MV</given-names></name><name><surname>Felice</surname><given-names>CA</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><etal></etal></person-group>:
<article-title>Oligodendrocyte lineage cells contribute unique features to Rett syndrome neuropathology.</article-title>
<source/><italic>J Neurosci.</italic>
<year>2013</year>;<volume>33</volume>(<issue>48</issue>):<fpage>18764</fpage>–<lpage>74</lpage>.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2657-13.2013</pub-id>
<!--<pub-id pub-id-type="pmcid">3841446</pub-id>-->
<pub-id pub-id-type="pmid">24285883</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718190020">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sharma</surname><given-names>K</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name><name><surname>Pillai</surname><given-names>PP</given-names></name><etal></etal></person-group>:
<article-title>Involvement of MeCP2 in Regulation of Myelin-Related Gene Expression in Cultured Rat Oligodendrocytes.</article-title>
<source/><italic>J Mol Neurosci.</italic>
<year>2015</year>;<volume>57</volume>(<issue>2</issue>):<fpage>176</fpage>–<lpage>84</lpage>.
<pub-id pub-id-type="doi">10.1007/s12031-015-0597-3</pub-id>
<pub-id pub-id-type="pmid">26140854</pub-id></mixed-citation>
</ref>
<ref id="ref-25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>JD</given-names></name><name><surname>Meehan</surname><given-names>RR</given-names></name><name><surname>Henzel</surname><given-names>WJ</given-names></name><etal></etal></person-group>:
<article-title>Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA.</article-title>
<source/><italic>Cell.</italic>
<year>1992</year>;<volume>69</volume>(<issue>6</issue>):<fpage>905</fpage>–<lpage>14</lpage>.
<pub-id pub-id-type="doi">10.1016/0092-8674(92)90610-O</pub-id>
<pub-id pub-id-type="pmid">1606614</pub-id></mixed-citation>
</ref>
<ref id="ref-26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>D'Esposito</surname><given-names>M</given-names></name><name><surname>Quaderi</surname><given-names>NA</given-names></name><name><surname>Ciccodicola</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Isolation, physical mapping, and northern analysis of the X-linked human gene encoding methyl CpG-binding protein, MECP2.</article-title>
<source/><italic>Mamm Genome.</italic>
<year>1996</year>;<volume>7</volume>(<issue>7</issue>):<fpage>533</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1007/s003359900157</pub-id>
<pub-id pub-id-type="pmid">8672133</pub-id></mixed-citation>
</ref>
<ref id="ref-27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Quaderi</surname><given-names>NA</given-names></name><name><surname>Meehan</surname><given-names>RR</given-names></name><name><surname>Tate</surname><given-names>PH</given-names></name><etal></etal></person-group>:
<article-title>Genetic and physical mapping of a gene encoding a methyl CpG binding protein,
<italic>Mecp2</italic>, to the mouse X chromosome.</article-title>
<source/><italic>Genomics.</italic>
<year>1994</year>;<volume>22</volume>(<issue>3</issue>):<fpage>648</fpage>–<lpage>51</lpage>.
<pub-id pub-id-type="doi">10.1006/geno.1994.1442</pub-id>
<pub-id pub-id-type="pmid">8001979</pub-id></mixed-citation>
</ref>
<ref id="ref-28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galvão</surname><given-names>TC</given-names></name><name><surname>Thomas</surname><given-names>JO</given-names></name></person-group>:
<article-title>Structure-specific binding of MeCP2 to four-way junction DNA through its methyl CpG-binding domain.</article-title>
<source/><italic>Nucleic Acids Res.</italic>
<year>2005</year>;<volume>33</volume>(<issue>20</issue>):<fpage>6603</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/gki971</pub-id>
<!--<pub-id pub-id-type="pmcid">1298929</pub-id>-->
<pub-id pub-id-type="pmid">16314321</pub-id></mixed-citation>
</ref>
<ref id="ref-29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mellén</surname><given-names>M</given-names></name><name><surname>Ayata</surname><given-names>P</given-names></name><name><surname>Dewell</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system.</article-title>
<source/><italic>Cell.</italic>
<year>2012</year>;<volume>151</volume>(<issue>7</issue>):<fpage>1417</fpage>–<lpage>30</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cell.2012.11.022</pub-id>
<!--<pub-id pub-id-type="pmcid">3653293</pub-id>-->
<pub-id pub-id-type="pmid">23260135</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/717968444">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>JU</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Shin</surname><given-names>JH</given-names></name><etal></etal></person-group>:
<article-title>Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain.</article-title>
<source/><italic>Nat Neurosci.</italic>
<year>2014</year>;<volume>17</volume>(<issue>2</issue>):<fpage>215</fpage>–<lpage>22</lpage>.
<pub-id pub-id-type="doi">10.1038/nn.3607</pub-id>
<!--<pub-id pub-id-type="pmcid">3970219</pub-id>-->
<pub-id pub-id-type="pmid">24362762</pub-id></mixed-citation>
</ref>
<ref id="ref-31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sugino</surname><given-names>K</given-names></name><name><surname>Hempel</surname><given-names>CM</given-names></name><name><surname>Okaty</surname><given-names>BW</given-names></name><etal></etal></person-group>:
<article-title>Cell-type-specific repression by methyl-CpG-binding protein 2 is biased toward long genes.</article-title>
<source/><italic>J Neurosci.</italic>
<year>2014</year>;<volume>34</volume>(<issue>38</issue>):<fpage>12877</fpage>–<lpage>83</lpage>.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2674-14.2014</pub-id>
<!--<pub-id pub-id-type="pmcid">4166166</pub-id>-->
<pub-id pub-id-type="pmid">25232122</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718880281">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gabel</surname><given-names>HW</given-names></name><name><surname>Kinde</surname><given-names>B</given-names></name><name><surname>Stroud</surname><given-names>H</given-names></name><etal></etal></person-group>:
<article-title>Disruption of DNA-methylation-dependent long gene repression in Rett syndrome.</article-title>
<source/><italic>Nature.</italic>
<year>2015</year>;<volume>522</volume>(<issue>7554</issue>):<fpage>89</fpage>–<lpage>93</lpage>.
<pub-id pub-id-type="doi">10.1038/nature14319</pub-id>
<!--<pub-id pub-id-type="pmcid">4480648</pub-id>-->
<pub-id pub-id-type="pmid">25762136</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725387513">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lagger</surname><given-names>S</given-names></name><name><surname>Connelly</surname><given-names>JC</given-names></name><name><surname>Schweikert</surname><given-names>G</given-names></name><etal></etal></person-group>:
<article-title>MeCP2 recognizes cytosine methylated tri-nucleotide and di-nucleotide sequences to tune transcription in the mammalian brain.</article-title>
<source/><italic>PLoS Genet.</italic>
<year>2017</year>;<volume>13</volume>(<issue>5</issue>):<fpage>e1006793</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pgen.1006793</pub-id>
<!--<pub-id pub-id-type="pmcid">5446194</pub-id>-->
<pub-id pub-id-type="pmid">28498846</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727608909">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stroud</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>SC</given-names></name><name><surname>Hrvatin</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Early-Life Gene Expression in Neurons Modulates Lasting Epigenetic States.</article-title>
<source/><italic>Cell.</italic>
<year>2017</year>;<volume>171</volume>(<issue>5</issue>):<fpage>1151</fpage>–<lpage>1164.e16</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cell.2017.09.047</pub-id>
<!--<pub-id pub-id-type="pmcid">5693680</pub-id>-->
<pub-id pub-id-type="pmid">29056337</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/732025725">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lyst</surname><given-names>MJ</given-names></name><name><surname>Ekiert</surname><given-names>R</given-names></name><name><surname>Ebert</surname><given-names>DH</given-names></name><etal></etal></person-group>:
<article-title>Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor.</article-title>
<source/><italic>Nat Neurosci.</italic>
<year>2013</year>;<volume>16</volume>(<issue>7</issue>):<fpage>898</fpage>–<lpage>902</lpage>.
<pub-id pub-id-type="doi">10.1038/nn.3434</pub-id>
<!--<pub-id pub-id-type="pmcid">3786392</pub-id>-->
<pub-id pub-id-type="pmid">23770565</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718021971">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tillotson</surname><given-names>R</given-names></name><name><surname>Selfridge</surname><given-names>J</given-names></name><name><surname>Koerner</surname><given-names>MV</given-names></name><etal></etal></person-group>:
<article-title>Radically truncated MeCP2 rescues Rett syndrome-like neurological defects.</article-title>
<source/><italic>Nature.</italic>
<year>2017</year>;<volume>550</volume>(<issue>7676</issue>):<fpage>398</fpage>–<lpage>401</lpage>.
<pub-id pub-id-type="doi">10.1038/nature24058</pub-id>
<pub-id pub-id-type="pmid">29019980</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/731966459">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-37">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baker</surname><given-names>SA</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wilkins</surname><given-names>AD</given-names></name><etal></etal></person-group>:
<article-title>An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders.</article-title>
<source/><italic>Cell.</italic>
<year>2013</year>;<volume>152</volume>(<issue>5</issue>):<fpage>984</fpage>–<lpage>96</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cell.2013.01.038</pub-id>
<!--<pub-id pub-id-type="pmcid">3641682</pub-id>-->
<pub-id pub-id-type="pmid">23452848</pub-id></mixed-citation>
</ref>
<ref id="ref-38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lyst</surname><given-names>MJ</given-names></name><name><surname>Connelly</surname><given-names>J</given-names></name><name><surname>Merusi</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Sequence-specific DNA binding by AT-hook motifs in MeCP2.</article-title>
<source/><italic>FEBS Lett.</italic>
<year>2016</year>;<volume>590</volume>(<issue>17</issue>):<fpage>2927</fpage>–<lpage>33</lpage>.
<pub-id pub-id-type="doi">10.1002/1873-3468.12328</pub-id>
<!--<pub-id pub-id-type="pmcid">5028900</pub-id>-->
<pub-id pub-id-type="pmid">27461740</pub-id></mixed-citation>
</ref>
<ref id="ref-39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><etal></etal></person-group>:
<article-title>Disruption of AT-hook 1 domain in MeCP2 protein caused behavioral abnormality in mice.</article-title>
<source/><italic>Biochim Biophys Acta.</italic>
<year>2018</year>;<volume>1864</volume>(<issue>2</issue>):<fpage>347</fpage>–<lpage>58</lpage>.
<pub-id pub-id-type="doi">10.1016/j.bbadis.2017.10.022</pub-id>
<pub-id pub-id-type="pmid">29074463</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/732041379">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gaj</surname><given-names>T</given-names></name><name><surname>Gersbach</surname><given-names>CA</given-names></name><name><surname>Barbas</surname><given-names>CF</given-names></name></person-group>:
<article-title>ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.</article-title>
<source/><italic>Trends Biotechnol.</italic>
<year>2013</year>;<volume>31</volume>(<issue>7</issue>):<fpage>397</fpage>–<lpage>405</lpage>.
<pub-id pub-id-type="doi">10.1016/j.tibtech.2013.04.004</pub-id>
<!--<pub-id pub-id-type="pmcid">3694601</pub-id>-->
<pub-id pub-id-type="pmid">23664777</pub-id></mixed-citation>
</ref>
<ref id="ref-41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Cui</surname><given-names>N</given-names></name><etal></etal></person-group>:
<article-title>Characterization of Rett Syndrome-like phenotypes in
<italic>Mecp2</italic>-knockout rats.</article-title>
<source/><italic>J Neurodev Disord.</italic>
<year>2016</year>;<volume>8</volume>:<fpage>23</fpage>.
<pub-id pub-id-type="doi">10.1186/s11689-016-9156-7</pub-id>
<!--<pub-id pub-id-type="pmcid">4910223</pub-id>-->
<pub-id pub-id-type="pmid">27313794</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726436778">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-42">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patterson</surname><given-names>KC</given-names></name><name><surname>Hawkins</surname><given-names>VE</given-names></name><name><surname>Arps</surname><given-names>KM</given-names></name><etal></etal></person-group>:
<article-title>MeCP2 deficiency results in robust Rett-like behavioural and motor deficits in male and female rats.</article-title>
<source/><italic>Hum Mol Genet.</italic>
<year>2016</year>;<volume>25</volume>(<issue>24</issue>):<fpage>5514</fpage>–<lpage>5515</lpage>.
<pub-id pub-id-type="doi">10.1093/hmg/ddw435</pub-id>
<pub-id pub-id-type="pmid">28201743</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726441666">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-43">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhattacherjee</surname><given-names>A</given-names></name><name><surname>Winter</surname><given-names>MK</given-names></name><name><surname>Eggimann</surname><given-names>LS</given-names></name><etal></etal></person-group>:
<article-title>Motor, Somatosensory, Viscerosensory and Metabolic Impairments in a Heterozygous Female Rat Model of Rett Syndrome.</article-title>
<source/><italic>Int J Mol Sci.</italic>
<year>2017</year>;<volume>19</volume>(<issue>1</issue>): pii: E97.
<pub-id pub-id-type="doi">10.3390/ijms19010097</pub-id>
<!--<pub-id pub-id-type="pmcid">5796047</pub-id>-->
<pub-id pub-id-type="pmid">29286317</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/732378792">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-44">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhattacherjee</surname><given-names>A</given-names></name><name><surname>Mu</surname><given-names>Y</given-names></name><name><surname>Winter</surname><given-names>MK</given-names></name><etal></etal></person-group>:
<article-title>Neuronal cytoskeletal gene dysregulation and mechanical hypersensitivity in a rat model of Rett syndrome.</article-title>
<source/><italic>Proc Natl Acad Sci U S A.</italic>
<year>2017</year>;<volume>114</volume>(<issue>33</issue>):<fpage>E6952</fpage>–<lpage>E6961</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1618210114</pub-id>
<!--<pub-id pub-id-type="pmcid">5565404</pub-id>-->
<pub-id pub-id-type="pmid">28760966</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727865884">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-45">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><etal></etal></person-group>:
<article-title>Generation of a monkey with
<italic>MECP2</italic> mutations by TALEN-based gene targeting.</article-title>
<source/><italic>Neurosci Bull.</italic>
<year>2014</year>;<volume>30</volume>(<issue>3</issue>):<fpage>381</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1007/s12264-014-1434-8</pub-id>
<!--<pub-id pub-id-type="pmcid">5562616</pub-id>-->
<pub-id pub-id-type="pmid">24838303</pub-id></mixed-citation>
</ref>
<ref id="ref-46">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Niu</surname><given-names>Y</given-names></name><etal></etal></person-group>:
<article-title>Modeling Rett Syndrome Using TALEN-Edited
<italic>MECP2</italic> Mutant Cynomolgus Monkeys.</article-title>
<source/><italic>Cell.</italic>
<year>2017</year>;<volume>169</volume>(<issue>5</issue>):<fpage>945</fpage>–<lpage>955.e10</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cell.2017.04.035</pub-id>
<!--<pub-id pub-id-type="pmcid">5540256</pub-id>-->
<pub-id pub-id-type="pmid">28525759</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727622463">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-47">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Okita</surname><given-names>K</given-names></name><name><surname>Nakagawa</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>Induction of pluripotent stem cells from fibroblast cultures.</article-title>
<source/><italic>Nat Protoc.</italic>
<year>2007</year>;<volume>2</volume>(<issue>12</issue>):<fpage>3081</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1038/nprot.2007.418</pub-id>
<pub-id pub-id-type="pmid">18079707</pub-id></mixed-citation>
</ref>
<ref id="ref-48">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>KY</given-names></name><name><surname>Zhong</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>Transcriptional regulation in pluripotent stem cells by methyl CpG-binding protein 2 (MeCP2).</article-title>
<source/><italic>Hum Mol Genet.</italic>
<year>2014</year>;<volume>23</volume>(<issue>4</issue>):<fpage>1045</fpage>–<lpage>55</lpage>.
<pub-id pub-id-type="doi">10.1093/hmg/ddt500</pub-id>
<!--<pub-id pub-id-type="pmcid">3900111</pub-id>-->
<pub-id pub-id-type="pmid">24129406</pub-id></mixed-citation>
</ref>
<ref id="ref-49">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andoh-Noda</surname><given-names>T</given-names></name><name><surname>Akamatsu</surname><given-names>W</given-names></name><name><surname>Miyake</surname><given-names>K</given-names></name><etal></etal></person-group>:
<article-title>Differentiation of multipotent neural stem cells derived from Rett syndrome patients is biased toward the astrocytic lineage.</article-title>
<source/><italic>Mol Brain.</italic>
<year>2015</year>;<volume>8</volume>:<fpage>31</fpage>.
<pub-id pub-id-type="doi">10.1186/s13041-015-0121-2</pub-id>
<!--<pub-id pub-id-type="pmcid">4446051</pub-id>-->
<pub-id pub-id-type="pmid">26012557</pub-id></mixed-citation>
</ref>
<ref id="ref-50">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>KCC2 rescues functional deficits in human neurons derived from patients with Rett syndrome.</article-title>
<source/><italic>Proc Natl Acad Sci U S A.</italic>
<year>2016</year>;<volume>113</volume>(<issue>3</issue>):<fpage>751</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1524013113</pub-id>
<!--<pub-id pub-id-type="pmcid">4725523</pub-id>-->
<pub-id pub-id-type="pmid">26733678</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726058262">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-51">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Castro</surname><given-names>J</given-names></name><name><surname>Garcia</surname><given-names>RI</given-names></name><name><surname>Kwok</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome.</article-title>
<source/><italic>Proc Natl Acad Sci U S A.</italic>
<year>2014</year>;<volume>111</volume>(<issue>27</issue>):<fpage>9941</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1311685111</pub-id>
<!--<pub-id pub-id-type="pmcid">4103342</pub-id>-->
<pub-id pub-id-type="pmid">24958891</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718465468">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-52">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guy</surname><given-names>J</given-names></name><name><surname>Gan</surname><given-names>J</given-names></name><name><surname>Selfridge</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>Reversal of neurological defects in a mouse model of Rett syndrome.</article-title>
<source/><italic>Science.</italic>
<year>2007</year>;<volume>315</volume>(<issue>5815</issue>):<fpage>1143</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1126/science.1138389</pub-id>
<pub-id pub-id-type="pmid">17289941</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/1066718">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-53">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gadalla</surname><given-names>KK</given-names></name><name><surname>Bailey</surname><given-names>ME</given-names></name><name><surname>Spike</surname><given-names>RC</given-names></name><etal></etal></person-group>:
<article-title>Improved survival and reduced phenotypic severity following AAV9/
<italic>MECP2</italic> gene transfer to neonatal and juvenile male
<italic>Mecp2</italic> knockout mice.</article-title>
<source/><italic>Mol Ther.</italic>
<year>2013</year>;<volume>21</volume>(<issue>1</issue>):<fpage>18</fpage>–<lpage>30</lpage>.
<pub-id pub-id-type="doi">10.1038/mt.2012.200</pub-id>
<!--<pub-id pub-id-type="pmcid">3536818</pub-id>-->
<pub-id pub-id-type="pmid">23011033</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/717959340">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-54">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garg</surname><given-names>SK</given-names></name><name><surname>Lioy</surname><given-names>DT</given-names></name><name><surname>Cheval</surname><given-names>H</given-names></name><etal></etal></person-group>:
<article-title>Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome.</article-title>
<source/><italic>J Neurosci.</italic>
<year>2013</year>;<volume>33</volume>(<issue>34</issue>):<fpage>13612</fpage>–<lpage>20</lpage>.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1854-13.2013</pub-id>
<!--<pub-id pub-id-type="pmcid">3755711</pub-id>-->
<pub-id pub-id-type="pmid">23966684</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718083156">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-55">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matagne</surname><given-names>V</given-names></name><name><surname>Ehinger</surname><given-names>Y</given-names></name><name><surname>Saidi</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>A codon-optimized
<italic>Mecp2</italic> transgene corrects breathing deficits and improves survival in a mouse model of Rett syndrome.</article-title>
<source/><italic>Neurobiol Dis.</italic>
<year>2017</year>;<volume>99</volume>:<fpage>1</fpage>–<lpage>11</lpage>.
<pub-id pub-id-type="doi">10.1016/j.nbd.2016.12.009</pub-id>
<pub-id pub-id-type="pmid">27974239</pub-id></mixed-citation>
</ref>
<ref id="ref-56">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gadalla</surname><given-names>KKE</given-names></name><name><surname>Vudhironarit</surname><given-names>T</given-names></name><name><surname>Hector</surname><given-names>RD</given-names></name><etal></etal></person-group>:
<article-title>Development of a Novel AAV Gene Therapy Cassette with Improved Safety Features and Efficacy in a Mouse Model of Rett Syndrome.</article-title>
<source/><italic>Mol Ther Methods Clin Dev.</italic>
<year>2017</year>;<volume>5</volume>:<fpage>180</fpage>–<lpage>90</lpage>.
<pub-id pub-id-type="doi">10.1016/j.omtm.2017.04.007</pub-id>
<!--<pub-id pub-id-type="pmcid">5423329</pub-id>-->
<pub-id pub-id-type="pmid">28497075</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727607080">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-57">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sinnett</surname><given-names>SE</given-names></name><name><surname>Hector</surname><given-names>RD</given-names></name><name><surname>Gadalla</surname><given-names>KKE</given-names></name><etal></etal></person-group>:
<article-title>Improved
<italic>MECP2</italic> Gene Therapy Extends the Survival of MeCP2-Null Mice without Apparent Toxicity after Intracisternal Delivery.</article-title>
<source/><italic>Mol Ther Methods Clin Dev.</italic>
<year>2017</year>;<volume>5</volume>:<fpage>106</fpage>–<lpage>15</lpage>.
<pub-id pub-id-type="doi">10.1016/j.omtm.2017.04.006</pub-id>
<!--<pub-id pub-id-type="pmcid">5424572</pub-id>-->
<pub-id pub-id-type="pmid">28497072</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727607094">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-58">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wojtal</surname><given-names>D</given-names></name><name><surname>Kemaladewi</surname><given-names>DU</given-names></name><name><surname>Malam</surname><given-names>Z</given-names></name><etal></etal></person-group>:
<article-title>Spell Checking Nature: Versatility of CRISPR/Cas9 for Developing Treatments for Inherited Disorders.</article-title>
<source/><italic>Am J Hum Genet.</italic>
<year>2016</year>;<volume>98</volume>(<issue>1</issue>):<fpage>90</fpage>–<lpage>101</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ajhg.2015.11.012</pub-id>
<!--<pub-id pub-id-type="pmcid">4716669</pub-id>-->
<pub-id pub-id-type="pmid">26686765</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726028128">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-59">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sinnamon</surname><given-names>JR</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Corson</surname><given-names>GM</given-names></name><etal></etal></person-group>:
<article-title>Site-directed RNA repair of endogenous Mecp2 RNA in neurons.</article-title>
<source/><italic>Proc Natl Acad Sci U S A.</italic>
<year>2017</year>;<volume>114</volume>(<issue>44</issue>):<fpage>E9395</fpage>–<lpage>E9402</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1715320114</pub-id>
<!--<pub-id pub-id-type="pmcid">5676935</pub-id>-->
<pub-id pub-id-type="pmid">29078406</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/732046007">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-60">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhatnagar</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Ou</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>Genetic and pharmacological reactivation of the mammalian inactive X chromosome.</article-title>
<source/><italic>Proc Natl Acad Sci U S A.</italic>
<year>2014</year>;<volume>111</volume>(<issue>35</issue>):<fpage>12591</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1413620111</pub-id>
<!--<pub-id pub-id-type="pmcid">4156765</pub-id>-->
<pub-id pub-id-type="pmid">25136103</pub-id></mixed-citation>
</ref>
<ref id="ref-61">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sripathy</surname><given-names>S</given-names></name><name><surname>Leko</surname><given-names>V</given-names></name><name><surname>Adrianse</surname><given-names>RL</given-names></name><etal></etal></person-group>:
<article-title>Screen for reactivation of MeCP2 on the inactive X chromosome identifies the BMP/TGF-β superfamily as a regulator of XIST expression.</article-title>
<source/><italic>Proc Natl Acad Sci U S A.</italic>
<year>2017</year>;<volume>114</volume>(<issue>7</issue>):<fpage>1619</fpage>–<lpage>24</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1621356114</pub-id>
<!--<pub-id pub-id-type="pmcid">5321041</pub-id>-->
<pub-id pub-id-type="pmid">28143937</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727259086">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-62">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carrette</surname><given-names>LLG</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Wei</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders.</article-title>
<source/><italic>Proc Natl Acad Sci U S A.</italic>
<year>2018</year>;<volume>115</volume>(<issue>4</issue>):<fpage>E668</fpage>–<lpage>E675</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1715124115</pub-id>
<!--<pub-id pub-id-type="pmcid">5789928</pub-id>-->
<pub-id pub-id-type="pmid">29282321</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/732372800">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-63">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abdala</surname><given-names>AP</given-names></name><name><surname>Lioy</surname><given-names>DT</given-names></name><name><surname>Garg</surname><given-names>SK</given-names></name><etal></etal></person-group>:
<article-title>Effect of Sarizotan, a 5-HT
<sub>1a</sub> and D2-like receptor agonist, on respiration in three mouse models of Rett syndrome.</article-title>
<source/><italic>Am J Respir Cell Mol Biol.</italic>
<year>2014</year>;<volume>50</volume>(<issue>6</issue>):<fpage>1031</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1165/rcmb.2013-0372OC</pub-id>
<!--<pub-id pub-id-type="pmcid">4068914</pub-id>-->
<pub-id pub-id-type="pmid">24351104</pub-id></mixed-citation>
</ref>
<ref id="ref-64">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patrizi</surname><given-names>A</given-names></name><name><surname>Picard</surname><given-names>N</given-names></name><name><surname>Simon</surname><given-names>AJ</given-names></name><etal></etal></person-group>:
<article-title>Chronic Administration of the
<italic>N</italic>-Methyl-D-Aspartate Receptor Antagonist Ketamine Improves Rett Syndrome Phenotype.</article-title>
<source/><italic>Biol Psychiatry.</italic>
<year>2016</year>;<volume>79</volume>(<issue>9</issue>):<fpage>755</fpage>–<lpage>64</lpage>.
<pub-id pub-id-type="doi">10.1016/j.biopsych.2015.08.018</pub-id>
<pub-id pub-id-type="pmid">26410354</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725813027">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-65">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roux</surname><given-names>JC</given-names></name><name><surname>Dura</surname><given-names>E</given-names></name><name><surname>Moncla</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome.</article-title>
<source/><italic>Eur J Neurosci.</italic>
<year>2007</year>;<volume>25</volume>(<issue>7</issue>):<fpage>1915</fpage>–<lpage>22</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2007.05466.x</pub-id>
<pub-id pub-id-type="pmid">17439480</pub-id></mixed-citation>
</ref>
<ref id="ref-66">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bittolo</surname><given-names>T</given-names></name><name><surname>Raminelli</surname><given-names>CA</given-names></name><name><surname>Deiana</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice.</article-title>
<source/><italic>Sci Rep.</italic>
<year>2016</year>;<volume>6</volume>:<fpage>19796</fpage>.
<pub-id pub-id-type="doi">10.1038/srep19796</pub-id>
<!--<pub-id pub-id-type="pmcid">4726391</pub-id>-->
<pub-id pub-id-type="pmid">26806603</pub-id></mixed-citation>
</ref>
<ref id="ref-67">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abdala</surname><given-names>AP</given-names></name><name><surname>Dutschmann</surname><given-names>M</given-names></name><name><surname>Bissonnette</surname><given-names>JM</given-names></name><etal></etal></person-group>:
<article-title>Correction of respiratory disorders in a mouse model of Rett syndrome.</article-title>
<source/><italic>Proc Natl Acad Sci U S A.</italic>
<year>2010</year>;<volume>107</volume>(<issue>42</issue>):<fpage>18208</fpage>–<lpage>13</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1012104107</pub-id>
<!--<pub-id pub-id-type="pmcid">2964253</pub-id>-->
<pub-id pub-id-type="pmid">20921395</pub-id></mixed-citation>
</ref>
<ref id="ref-68">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>Q</given-names></name><name><surname>Khare</surname><given-names>G</given-names></name><name><surname>Dani</surname><given-names>V</given-names></name><etal></etal></person-group>:
<article-title>The disease progression of
<italic>Mecp2</italic> mutant mice is affected by the level of BDNF expression.</article-title>
<source/><italic>Neuron.</italic>
<year>2006</year>;<volume>49</volume>(<issue>3</issue>):<fpage>341</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neuron.2005.12.027</pub-id>
<pub-id pub-id-type="pmid">16446138</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/1031286">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-69">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Larimore</surname><given-names>JL</given-names></name><name><surname>Chapleau</surname><given-names>CA</given-names></name><name><surname>Kudo</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>
<italic>Bdnf</italic> overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated
<italic>MECP2</italic> mutations.</article-title>
<source/><italic>Neurobiol Dis.</italic>
<year>2009</year>;<volume>34</volume>(<issue>2</issue>):<fpage>199</fpage>–<lpage>211</lpage>.
<pub-id pub-id-type="doi">10.1016/j.nbd.2008.12.011</pub-id>
<!--<pub-id pub-id-type="pmcid">2726722</pub-id>-->
<pub-id pub-id-type="pmid">19217433</pub-id></mixed-citation>
</ref>
<ref id="ref-70">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Pozzo-Miller</surname><given-names>L</given-names></name></person-group>:
<article-title>BDNF deregulation in Rett syndrome.</article-title>
<source/><italic>Neuropharmacology.</italic>
<year>2014</year>;<volume>76 Pt C</volume>:<fpage>737</fpage>–<lpage>46</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.03.024</pub-id>
<!--<pub-id pub-id-type="pmcid">3773283</pub-id>-->
<pub-id pub-id-type="pmid">23597512</pub-id></mixed-citation>
</ref>
<ref id="ref-71">
<label>71</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deogracias</surname><given-names>R</given-names></name><name><surname>Yazdani</surname><given-names>M</given-names></name><name><surname>Dekkers</surname><given-names>MP</given-names></name><etal></etal></person-group>:
<article-title>Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome.</article-title>
<source/><italic>Proc Natl Acad Sci U S A.</italic>
<year>2012</year>;<volume>109</volume>(<issue>35</issue>):<fpage>14230</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1206093109</pub-id>
<!--<pub-id pub-id-type="pmcid">3435172</pub-id>-->
<pub-id pub-id-type="pmid">22891354</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/723896659">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-72">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Djukic</surname><given-names>A</given-names></name><name><surname>Holtzer</surname><given-names>R</given-names></name><name><surname>Shinnar</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate.</article-title>
<source/><italic>Pediatr Neurol.</italic>
<year>2016</year>;<volume>61</volume>:<fpage>51</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2016.05.010</pub-id>
<pub-id pub-id-type="pmid">27363291</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727320502">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-73">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nissenkorn</surname><given-names>A</given-names></name><name><surname>Kidon</surname><given-names>M</given-names></name><name><surname>Ben-Zeev</surname><given-names>B</given-names></name></person-group>:
<article-title>A Potential Life-Threatening Reaction to Glatiramer Acetate in Rett Syndrome.</article-title>
<source/><italic>Pediatr Neurol.</italic>
<year>2017</year>;<volume>68</volume>:<fpage>40</fpage>–<lpage>3</lpage>.
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2016.11.006</pub-id>
<pub-id pub-id-type="pmid">28254244</pub-id></mixed-citation>
</ref>
<ref id="ref-74">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tropea</surname><given-names>D</given-names></name><name><surname>Mortimer</surname><given-names>N</given-names></name><name><surname>Bellini</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Expression of nuclear Methyl-CpG binding protein 2 (Mecp2) is dependent on neuronal stimulation and application of Insulin-like growth factor 1.</article-title>
<source/><italic>Neurosci Lett.</italic>
<year>2016</year>;<volume>621</volume>:<fpage>111</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neulet.2016.04.024</pub-id>
<pub-id pub-id-type="pmid">27080430</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726288513">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-75">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khwaja</surname><given-names>OS</given-names></name><name><surname>Ho</surname><given-names>E</given-names></name><name><surname>Barnes</surname><given-names>KV</given-names></name><etal></etal></person-group>:
<article-title>Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome.</article-title>
<source/><italic>Proc Natl Acad Sci U S A.</italic>
<year>2014</year>;<volume>111</volume>(<issue>12</issue>):<fpage>4596</fpage>–<lpage>601</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1311141111</pub-id>
<!--<pub-id pub-id-type="pmcid">3970488</pub-id>-->
<pub-id pub-id-type="pmid">24623853</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718308943">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-76">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pini</surname><given-names>G</given-names></name><name><surname>Congiu</surname><given-names>L</given-names></name><name><surname>Benincasa</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Illness Severity, Social and Cognitive Ability, and EEG Analysis of Ten Patients with Rett Syndrome Treated with Mecasermin (Recombinant Human IGF-1).</article-title>
<source/><italic>Autism Res Treat.</italic>
<year>2016</year>;<volume>2016</volume>:<fpage>5073078</fpage>.
<pub-id pub-id-type="doi">10.1155/2016/5073078</pub-id>
<!--<pub-id pub-id-type="pmcid">4746298</pub-id>-->
<pub-id pub-id-type="pmid">26925263</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726182566">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-77">
<label>77</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O'Leary</surname><given-names>HM</given-names></name><name><surname>Kaufmann</surname><given-names>WE</given-names></name><name><surname>Barnes</surname><given-names>KV</given-names></name><etal></etal></person-group>:
<article-title>Placebo-controlled crossover assessment of mecasermin for the treatment of Rett syndrome.</article-title>
<source/><italic>Ann Clin Transl Neurol.</italic>
<year>2018</year>;<volume>5</volume>(<issue>3</issue>):<fpage>323</fpage>–<lpage>32</lpage>.
<pub-id pub-id-type="doi">10.1002/acn3.533</pub-id>
<!--<pub-id pub-id-type="pmcid">5846450</pub-id>-->
<pub-id pub-id-type="pmid">29560377</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/732634464">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-78">
<label>78</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pini</surname><given-names>G</given-names></name><name><surname>Scusa</surname><given-names>MF</given-names></name><name><surname>Congiu</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients.</article-title>
<source/><italic>Autism Res Treat.</italic>
<year>2012</year>;<volume>2012</volume>:<fpage>679801</fpage>.
<pub-id pub-id-type="doi">10.1155/2012/679801</pub-id>
<!--<pub-id pub-id-type="pmcid">3420537</pub-id>-->
<pub-id pub-id-type="pmid">22934177</pub-id></mixed-citation>
</ref>
<ref id="ref-79">
<label>79</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glaze</surname><given-names>DG</given-names></name><name><surname>Neul</surname><given-names>JL</given-names></name><name><surname>Percy</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome.</article-title>
<source/><italic>Pediatr Neurol.</italic>
<year>2017</year>;<volume>76</volume>:<fpage>37</fpage>–<lpage>46</lpage>.
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2017.07.002</pub-id>
<pub-id pub-id-type="pmid">28964591</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/730848651">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-80">
<label>80</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>El-Khoury</surname><given-names>R</given-names></name><name><surname>Panayotis</surname><given-names>N</given-names></name><name><surname>Matagne</surname><given-names>V</given-names></name><etal></etal></person-group>:
<article-title>GABA and glutamate pathways are spatially and developmentally affected in the brain of
<italic>Mecp2</italic>-deficient mice.</article-title>
<source/><italic>PLoS One.</italic>
<year>2014</year>;<volume>9</volume>(<issue>3</issue>):<fpage>e92169</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0092169</pub-id>
<!--<pub-id pub-id-type="pmcid">3965407</pub-id>-->
<pub-id pub-id-type="pmid">24667344</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718325882">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-81">
<label>81</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith-Hicks</surname><given-names>CL</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Ewen</surname><given-names>JB</given-names></name><etal></etal></person-group>:
<article-title>Randomized open-label trial of dextromethorphan in Rett syndrome.</article-title>
<source/><italic>Neurology.</italic>
<year>2017</year>;<volume>89</volume>(<issue>16</issue>):<fpage>1684</fpage>–<lpage>90</lpage>.
<pub-id pub-id-type="doi">10.1212/WNL.0000000000004515</pub-id>
<!--<pub-id pub-id-type="pmcid">5644464</pub-id>-->
<pub-id pub-id-type="pmid">28931647</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/731253535">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-82">
<label>82</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grosser</surname><given-names>E</given-names></name><name><surname>Hirt</surname><given-names>U</given-names></name><name><surname>Janc</surname><given-names>OA</given-names></name><etal></etal></person-group>:
<article-title>Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome.</article-title>
<source/><italic>Neurobiol Dis.</italic>
<year>2012</year>;<volume>48</volume>(<issue>1</issue>):<fpage>102</fpage>–<lpage>14</lpage>.
<pub-id pub-id-type="doi">10.1016/j.nbd.2012.06.007</pub-id>
<pub-id pub-id-type="pmid">22750529</pub-id></mixed-citation>
</ref>
<ref id="ref-83">
<label>83</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Felice</surname><given-names>C</given-names></name><name><surname>Della Ragione</surname><given-names>F</given-names></name><name><surname>Signorini</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome.</article-title>
<source/><italic>Neurobiol Dis.</italic>
<year>2014</year>;<volume>68</volume>:<fpage>66</fpage>–<lpage>77</lpage>.
<pub-id pub-id-type="doi">10.1016/j.nbd.2014.04.006</pub-id>
<!--<pub-id pub-id-type="pmcid">4076513</pub-id>-->
<pub-id pub-id-type="pmid">24769161</pub-id></mixed-citation>
</ref>
<ref id="ref-84">
<label>84</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pecorelli</surname><given-names>A</given-names></name><name><surname>Cervellati</surname><given-names>C</given-names></name><name><surname>Hayek</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>OxInflammation in Rett syndrome.</article-title>
<source/><italic>Int J Biochem Cell Biol.</italic>
<year>2016</year>;<volume>81</volume>(<issue>Pt B</issue>):<fpage>246</fpage>–<lpage>53</lpage>.
<pub-id pub-id-type="doi">10.1016/j.biocel.2016.07.015</pub-id>
<pub-id pub-id-type="pmid">27425398</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726546145">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-85">
<label>85</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Signorini</surname><given-names>C</given-names></name><name><surname>De Felice</surname><given-names>C</given-names></name><name><surname>Leoncini</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>Altered erythrocyte membrane fatty acid profile in typical Rett syndrome: effects of omega-3 polyunsaturated fatty acid supplementation.</article-title>
<source/><italic>Prostaglandins Leukot Essent Fatty Acids.</italic>
<year>2014</year>;<volume>91</volume>(<issue>5</issue>):<fpage>183</fpage>–<lpage>93</lpage>.
<pub-id pub-id-type="doi">10.1016/j.plefa.2014.08.002</pub-id>
<pub-id pub-id-type="pmid">25240461</pub-id></mixed-citation>
</ref>
<ref id="ref-86">
<label>86</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maffei</surname><given-names>S</given-names></name><name><surname>De Felice</surname><given-names>C</given-names></name><name><surname>Cannarile</surname><given-names>P</given-names></name><etal></etal></person-group>:
<article-title>Effects of
<italic>ω</italic>-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome.</article-title>
<source/><italic>Mediators Inflamm.</italic>
<year>2014</year>;<volume>2014</volume>:<fpage>983178</fpage>.
<pub-id pub-id-type="doi">10.1155/2014/983178</pub-id>
<!--<pub-id pub-id-type="pmcid">3913460</pub-id>-->
<pub-id pub-id-type="pmid">24526821</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>